The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA ...

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...

The regulatory environment is placing extreme pricing pressure on pharmaceutical manufacturers. Their success in the market ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

BMN 390 fell short of an immunogenicity threshold that BioMarin was looking for to support its further development. Employees ...

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

Leslie Zhen Liang is an award-winning investigative health and science journalist with a decade of experience covering ...

Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...